Genelux Corp. (GNLX) Price & Analysis

Compare

268 Followers

GNLX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.99 - $5.89

Previous CloseN/A

Volume23.79K

Average Volume (3M)142.46K

Market Cap

$166.20M

Enterprise Value$82.64M

Total Cash (Recent Filing)$27.97M

Total Debt (Recent Filing)$1.71M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Nov 12, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding37,773,440

10 Day Avg. Volume129,545

30 Day Avg. Volume142,463

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue92.23

Enterprise Value/Gross Profit-139.12

Enterprise Value/Ebitda-2.71

Forecast

1Y Price Target

$18.50

Price Target Upside320.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPositive initial data from a Phase 1b/2 study showed that Olvi-Vec combined with platinum chemotherapy achieved a 71% disease control rate in small cell lung cancer patients.

Financial PositionAn equity financing of $10.5M, along with existing cash reserves, is expected to provide financial stability into 2026, supporting ongoing clinical trials.

Regulatory ProgressThe FDA's recommendation for an interim overall survival analysis in the ovarian cancer trial may support full approval without needing a confirmatory trial.

Bears Say

Efficacy ChallengesPatients receiving Olvi-Vec for recurrent non-small cell lung cancer have already progressed on checkpoint inhibitors, suggesting potentially lower expected efficacy.

Financial PerformanceDespite having a cash runway expected to last into the second half of 2026, Genelux reported a net loss, which may indicate financial challenges.

Genelux Corp. News

Genelux Corp. Lowers Stock Option Exercise Prices

Genelux Corp. ( ($GNLX) ) just unveiled an update. On September 1, 2025, Genelux Corporation’s Board of Directors...

30d ago

GNLX

Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating

Bruce Jackson, an analyst from Benchmark Co., maintained the Buy rating on Genelux Corp.. The associated price target...

2M ago

GNLX

Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday....

2M ago

GNLX

Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of...

2M ago

GNLX

Genelux reports Q2 EPS (20c), consensus (22c)

“With important data milestones on the horizon, Olvi-Vec holds the potential to redefine the treatment paradigms of recurrent...

2M ago

GNLX

Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Genelux Corp.. The associated price target...

2M ago

GNLX

Genelux initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a...

2M ago

GNLX

Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Genelux Corp., retaining the price target of...

3M ago

GNLX

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

Genelux Corporation (GNLX) announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and...

3M ago

GNLX

RANI

Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Genelux Corp. (GNLX – Research Report), retaining...

5M ago

GNLX

Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Genelux Corp. (GNLX – Research Report)....

5M ago

GNLX

Genelux reports Q1 EPS (21c), consensus (24c)

“The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead....

5M ago

GNLX

Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Genelux Corp. (GNLX – Research Report) and...

6M ago

GNLX

Genelux reports FY24 EPS (95c), consensus (88c)

“Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our...

6M ago

GNLX

GNLX FAQ

What was Genelux Corp.’s price range in the past 12 months?

Genelux Corp. lowest stock price was $1.99 and its highest was $5.88 in the past 12 months.

What is Genelux Corp.’s market cap?

Genelux Corp.’s market cap is $166.20M.

When is Genelux Corp.’s upcoming earnings report date?

Genelux Corp.’s upcoming earnings report date is Nov 12, 2025 which is in 40 days.

How were Genelux Corp.’s earnings last quarter?

Genelux Corp. released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.216 by $0.016.

Is Genelux Corp. overvalued?

According to Wall Street analysts Genelux Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genelux Corp. pay dividends?

Genelux Corp. does not currently pay dividends.

What is Genelux Corp.’s EPS estimate?

Genelux Corp.’s EPS estimate is -0.22.

How many shares outstanding does Genelux Corp. have?

Genelux Corp. has 37,773,440 shares outstanding.

What happened to Genelux Corp.’s price movement after its last earnings report?

Genelux Corp. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.216. Following the earnings report the stock price went down -5.689%.

Which hedge fund is a major shareholder of Genelux Corp.?

Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 0.

Genelux Corp. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-98.72%

Trailing 12-Months

Asset Growth

-28.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genelux Corp.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corp. (GNLX) Earnings & Revenues

Historic Earnings Reports

GNLX Stock 12 Month Forecast

Average Price Target

$18.50

▲(320.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","8":"$8","16":"$16","24":"$24","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,8,16,24,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.37,5.495384615384616,7.6207692307692305,9.746153846153845,11.87153846153846,13.996923076923075,16.122307692307693,18.247692307692308,20.373076923076923,22.498461538461537,24.623846153846152,26.749230769230767,28.874615384615385,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.37,4.533846153846154,5.697692307692307,6.861538461538461,8.025384615384615,9.189230769230768,10.353076923076923,11.516923076923078,12.68076923076923,13.844615384615384,15.008461538461539,16.17230769230769,17.336153846153845,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.37,3.88,4.390000000000001,4.9,5.41,5.92,6.43,6.94,7.45,7.96,8.469999999999999,8.98,9.49,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >